141 related articles for article (PubMed ID: 37023446)
1. Systemic Progestins and Progestin-Releasing Intrauterine Device Therapy for Premenopausal Patients With Endometrial Intraepithelial Neoplasia.
Suzuki Y; Chen L; Hou JY; St Clair CM; Khoury-Collado F; de Meritens AB; Matsuo K; Melamed A; Hershman DL; Wright JD
Obstet Gynecol; 2023 May; 141(5):979-987. PubMed ID: 37023446
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis.
Suzuki Y; Ferris JS; Chen L; Dioun S; Usseglio J; Matsuo K; Xu X; Hershman DL; Wright JD
J Natl Cancer Inst; 2024 May; 116(5):653-664. PubMed ID: 38305500
[TBL] [Abstract][Full Text] [Related]
3. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
6. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
7. Oncological and reproductive outcomes for gonadotropin-releasing hormone agonist combined with aromatase inhibitors or levonorgestrel-releasing intra-uterine system in women with endometrial cancer or atypical endometrial hyperplasia.
Chen J; Cao D; Yang J; Yu M; Zhou H; Cheng N; Wang J; Zhang Y; Peng P; Shen K
Int J Gynecol Cancer; 2022 Dec; 32(12):1561-1567. PubMed ID: 36368706
[TBL] [Abstract][Full Text] [Related]
8. Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia.
Matsuo K; Mandelbaum RS; Ciccone M; Khoshchehreh M; Pursuwani H; Morocco EB; Matsuzaki S; Dancz CE; Ozel B; Paulson RJ; Roman L
Int J Gynecol Cancer; 2020 Sep; 30(9):1331-1339. PubMed ID: 32376736
[TBL] [Abstract][Full Text] [Related]
9. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
Luukkainen T; Toivonen J
Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
[TBL] [Abstract][Full Text] [Related]
10. Hormonal intrauterine devices.
Rybo G; Andersson K; Odlind V
Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
[TBL] [Abstract][Full Text] [Related]
11. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
12. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
13. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
14. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
15. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
16. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy.
Bourdrez P; Bongers MY; Mol BW
Fertil Steril; 2004 Jul; 82(1):160-6, quiz 265. PubMed ID: 15237006
[TBL] [Abstract][Full Text] [Related]
17. Conservatively treated endometrial intraepithelial neoplasia/cancer: Risk of intrauterine synechiae.
Cordeiro Mitchell CN; Hunkler KF; Maher JY; Garbose RA; Gornet ME; Whiting-Collins LJ; Christianson MS
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101930. PubMed ID: 33022448
[TBL] [Abstract][Full Text] [Related]
18. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
Mittermeier T; Farrant C; Wise MR
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
[TBL] [Abstract][Full Text] [Related]
19. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
Abu Hashim H; Ghayaty E; El Rakhawy M
Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia.
Ciccone MA; Whitman SA; Conturie CL; Brown N; Dancz CE; Özel B; Matsuo K
Arch Gynecol Obstet; 2019 Mar; 299(3):801-808. PubMed ID: 30706187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
